AMENDMENTS TO THE CLAIMS

1. - 38. (Canceled)

- 39. (Currently Amended) A method for the treatment of tumors wherein the lethal dose of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is increased to twice or more, the toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, gastrointestinal toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, hepatic toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, and/or cardiovascular toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, which comprises administering to a subject in need thereof a composition comprising
- (a) an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting

 Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and
- (b) (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof.
- 40. (Previously Presented) The method according to Claim 39, wherein said subject in need thereof is a human.

- 41. (Previously Presented) The method according to Claim 39, wherein said effective amount of said (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof ranges from 0.1-10000mg per day.
- 42. (Previously Presented) The method according to Claim 39, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.
 - 43. 49. (Canceled)
- 50. (Previously Presented) The method according to Claim 39, wherein (a) and (b) are administered simultaneously.
- 51. (Previously Presented) The method according to Claim 39, wherein (a) and (b) are administered sequentially.
- 52. (Previously Presented) The method according to Claim 39, wherein (a) is Dexamethasone.
- 53. (Previously Presented) The method according to Claim 39, wherein (a) is an ester of Dexamethasone.
- 54. (Previously Presented) The method according to Claim 39, wherein (a) is a salt of Dexamethasone.

- 55. (Previously Presented) The method according to Claim 39, wherein (b) is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.
- 56. (Previously Presented) The method according to Claim 39, wherein (b) is a salt of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.
- 57. (New) The method according to Claim 39, wherein said method increases the lethal dose of AC-7700 to twice or more.
- 58. (New) The method according to Claim 39, wherein said method reduces the toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.
- 59. (New) The method according to Claim 39, wherein said method reduces gastrointestinal toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.
- 60. (New) The method according to Claim 59, wherein said gastrointestinal toxicity is diarrhea.
- 61. (New) The method according to Claim 39, wherein said method reduces hepatic toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

Application Serial No. 10/743,997 Reply to Office Action of February 9, 2009 and the Notice mailed August 3, 2009

- 62. (New) The method according to Claim 61, wherein said reducing hepatic toxicity is lowering of GPT.
- 63. (New) The method according to Claim 39, wherein said method reduces cardiovascular toxicity at the pharmaceutically effective dosage of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.
- 64. (New) The method according to Claim 63, wherein said reducing cardiovascular toxicity is lowering of CPK.